Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics’ Product, Leukine®

For Immediate Release

Contact:
Lindsey Stevens
Tanner Pharma Group
704-552-8407
lstevens@tannerpharma.com

CHARLOTTE, N.C.Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Partner Therapeutics, Inc. (PTx), an integrated biopharmaceutical company. The agreement names Tanner Pharma Group as a distributor of Leukine® (sargramostim) in areas outside of the United States and Canada where the product is not yet registered. Leukine® (sargramostim) is used to help increase the number and function of white blood cells after bone marrow transplantation.

The ex-US-and-Canadian distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turnkey global access solutions for the distribution of products from markets of supply to markets of demand.

Banks Bourne, Chairman and Founder of Tanner Pharma Group, commented, “We have customized a program for Partner Therapeutics through which we can fulfill healthcare provider requests for Leukine® (sargramostim) in countries outside the US and Canadian markets. TannerGAP is pleased to be working with Partner Therapeutics to expand the distribution of Leukine® (sargramostim) to patients in need around the world.”

Robert Mulroy, CEO of Partner Therapeutics, added, “We are pleased to be working with Tanner to support a named patient access program to help meet the significant demand for Leukine® outside of North America. Tanner has proven capabilities to support physicians and help patients worldwide gain access to critical medicines and we look forward to working in partnership to improve access and treatments.”

About Partner Therapeutics (PTx)

PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer. PTx’s development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products in support of medical teams with the purpose of creating the best possible outcomes for patients and their families. For more information, visit www.PartnerTx.com.


About Tanner Pharma Group

For over 16 years, Tanner Pharma Group has partnered with biopharmaceutical companies to provide turn-key commercialization solutions to increase patient access to medicines around the world. By partnering with Tanner Pharma, biotech and pharma companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.

Tanner Pharma believes that access to medicines should have no borders and measures its value as a company based on the lives it helps to improve. With an unparalleled blend of local market knowledge, international supply chain expertise across more than 130 countries, and high regulatory compliance and quality standards, it provides tailored solutions to biopharmaceutical companies outside their core markets of focus.

Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America.

For more information about Tanner Pharma Group, please visit www.tannerpharma.com.

Contact Us